

Supplement to the article entitled:

The risk of multiple sclerosis relapse after yellow-fever vaccination: a self-
controlled case series

Angela Huttner^{1,2}, Gilles Eperon³, Agustina M. Lascano⁴, Serge Roth⁴, Jean-Marc Schwob³, Claire-Anne Siegrist^{1,5}, Patrice H. Lalive^{4,5,6*}

¹Center for Vaccinology, University of Geneva

²Division of Infectious Diseases, Geneva University Hospitals

³Division of Tropical and Humanitarian Medicine, Geneva University Hospitals

⁴Department of Neurosciences, Division of Neurology, Unit of Neuroimmunology and Neuromuscular Diseases, Geneva University Hospitals, Geneva, Switzerland

⁵Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

⁶Division of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland

*Corresponding author:

Division of Neurology

Geneva University Hospitals

Rue Gabrielle-Perret-Gentil 4

1205 Geneva, Switzerland

Tel. +41 22 3728318

Fax: +41 22 3728332

patrice.lalive@hcuge.ch

Figure S1: Study timeline, with predefined pre-exposure (PEP), exposure (ERP), and post-risk periods (PRP).





Figure S2. Study flow diagram.



YF: yellow fever; YFV: yellow-fever vaccine.